Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 13Thoracic 4Head & Neck 3Genitourinary 3CNS 3Sarcoma 2Breast 2Other solid neoplasm 1Gynecologic 1Dermatologic 1

Conditions

Breast Neoplasms 25Breast Neoplasms, Male 6Triple Negative Breast Neoplasms 4Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Lung Neoplasms 2Colonic Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thrombocytosis 1Thoracic Neoplasms 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Rectal Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Neoplasms by Site 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Mesothelioma, Malignant 1

Interventions

Psychiatric Rehabilitation 8Magnetic Resonance Spectroscopy 7Gemcitabine 7Capecitabine 7pembrolizumab 6Early Intervention, Educational 6Drug Therapy 6Cyclophosphamide 6Methods 5Therapeutics 4Specimen Handling 4Mental Status and Dementia Tests 4Docetaxel 4veliparib 3selpercatinib 3sargramostim 3palbociclib 3cediranib 3Trastuzumab 3Surveys and Questionnaires 3Standard of Care 3Radiotherapy 3Paclitaxel 3Oxaliplatin 3Irinotecan 3Fluorodeoxyglucose F18 3Counseling 3Cisplatin 3Carboplatin 3Bortezomib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Colonic Neoplasms × Erlotinib Hydrochloride × Breast × Clear all
NCT00600496 2026-05-27

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

AstraZeneca

Phase 1 Completed
140 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

NCT00030498 2013-01-16

Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction

National Cancer Institute (NCI)

Phase 1 Completed
75 enrolled
BreastCNSGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Mesothelioma, Malignant, Anus Neoplasms, Astrocytoma, Urinary Bladder Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Colonic Neoplasms, Ependymoma, Esophageal Neoplasms, Glioblastoma, Glioma, Carcinoma, Hepatocellular, Oligodendroglioma, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Neuroectodermal Tumors, Primitive, Esthesioneuroblastoma, Olfactory, Glioma, Subependymal, Gliosarcoma, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡